<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab2">
 <label>Table 2</label>
 <caption>
  <p>Select new FDA-approved antibiotics on the market in the USA since year 2017 Google Scholar and Medscape Search [
   <xref ref-type="bibr" rid="CR25">25</xref>–
   <xref ref-type="bibr" rid="CR27">27</xref>]
  </p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Drug class</th>
    <th>Names and notes</th>
    <th>Indications</th>
    <th>Select side effects</th>
    <th>Comments</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Aminomethylcyclines</td>
    <td>Omadacycline</td>
    <td>Skin and soft tissue infections, pneumonia caused by Gram-positive pathogens including MRSA, 
     <italic>S. pneumonia</italic> and VRE, some Gram negatives, Fragilis, Legionella, and Chlamydia
    </td>
    <td>Similar to newer tetracyclines such as doxycycline</td>
    <td>In trials for pneumonia treatment mortality rate was higher in omadacycline group</td>
   </tr>
   <tr>
    <td>Tetracyclines</td>
    <td>Sarecycline</td>
    <td>Approved for treatment of acne vulgaris.</td>
    <td>Similar to newer tetracyclines such as doxycycline</td>
    <td/>
   </tr>
   <tr>
    <td>Tetracyclines</td>
    <td>Eravacycline</td>
    <td>Complicated intraabdominal infections have broad-spectrum activity for treatment of Gram+ and Gram− intraabdominal infections</td>
    <td>Infusion site reaction, tetracycline class adverse reactions</td>
    <td>Related to tigecycline. Not approved for urinary tract infections</td>
   </tr>
   <tr>
    <td>Aminoglycoside</td>
    <td>Plazomicin</td>
    <td>Complicated UTI and ventilator-associated pneumonia [
     <xref ref-type="bibr" rid="CR28">28</xref>] caused by Gram-negative pathogens when no other treatment option exists
    </td>
    <td>Acute kidney injury, especially in patients with renal disease. Aminoglycoside class adverse reaction including at times irreversible ototoxicity, especially in patients with family history of hearing problems and neuromuscular blockade, especially in patients with preexisting neuromuscular disorders</td>
    <td/>
   </tr>
   <tr>
    <td>Nitroimidazole</td>
    <td>Pretomanid</td>
    <td>Limited patient populations with extensively drug resistant or non-responsive with multidrug-resistant 
     <italic>M. tuberculosis</italic> infection only in combination with bedaquiline and linezolid
    </td>
    <td>Hepatotoxicity, myelosuppression, neurotoxicity, QT prolongation, lactic acidosis, multiple drug-drug interactions</td>
    <td/>
   </tr>
   <tr>
    <td>Fluoroquinolones</td>
    <td>Delafloxacin [
     <xref ref-type="bibr" rid="CR29">29</xref>]
    </td>
    <td>Broad spectrum including MRSA, other Gram positives and Gram negatives for skin and soft tissue infections</td>
    <td>Carries the same black box warning as other fluoroquinolones, appears to have less QTc prolongation compared to other fluoroquinolones</td>
    <td/>
   </tr>
   <tr>
    <td>Rifamycins</td>
    <td>Rifamycin</td>
    <td>Traveler’s diarrhea caused by noninvasive 
     <italic>E. coli</italic> in adults
    </td>
    <td>Dyspepsia; generally low risk of side effects</td>
    <td>Not for patient with diarrhea associated with fever or bloody stools</td>
   </tr>
   <tr>
    <td>Nitroimidazole</td>
    <td>Secnidazole</td>
    <td>Treatment of bacterial vaginosis</td>
    <td>Candidal vulvovaginitis</td>
    <td>Single-dose treatment</td>
   </tr>
   <tr>
    <td>Carbapenem with β lactam inhibitor</td>
    <td>Meropenem/vaborbactam</td>
    <td>Complicated UTIs caused by Gram-negative organisms</td>
    <td>Risk of seizures with meropenem in patients with CNS disorders, reduced valproic acid serum concentration</td>
    <td/>
   </tr>
   <tr>
    <td>Cephalosporin</td>
    <td>Cefideracol [
     <xref ref-type="bibr" rid="CR30">30</xref>]
    </td>
    <td>Complicated UTIs caused by MDR Gram negatives with no other option, has been used for treatment of ventilator-associated pneumonia [
     <xref ref-type="bibr" rid="CR28">28</xref>]
    </td>
    <td/>
    <td>Increased mortality in critically ill patient with pneumonia or sepsis with carbapenem-resistant pathogens observed</td>
   </tr>
   <tr>
    <td>Pleuromutilin</td>
    <td>Lefamulin</td>
    <td>Community-acquired pneumonia, active against S. pneumonia, H. flu, Legionella, C. pneumonia, MSSA, mycoplasma</td>
    <td>Potential for QT prolongation, fetal toxicity, multiple drug-drug interactions</td>
    <td>Oral and injectable formulations are available</td>
   </tr>
   <tr>
    <td>Imipenem/cilastatin/relebactam</td>
    <td>Carbapenem/dehydropeptidase inhibitor/B-lactamase inhibitor</td>
    <td>Complicated UTIs and intraabdominal infection in patients where no alternative treatment is available</td>
    <td>Risk of seizures with carbapenem antibiotics in patients with CNS disorders may decrease valproic acid serum concentrations</td>
    <td/>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>VRE</italic> vancomycin-resistant enterococcus, 
   <italic>MDR</italic> multidrug resistant, 
   <italic>MSSA</italic> methicillin-sensitive 
   <italic>Staphylococcus aureus</italic>, 
   <italic>MRSA</italic> methicillin-resistant 
   <italic>Staphylococcus aureus</italic>
  </p>
 </table-wrap-foot>
</table-wrap>
